www.rheumatologyadvisor.com
Open in
urlscan Pro
2606:4700::6812:19c3
Public Scan
Submitted URL: https://app.info.haymarketmedicalnetwork.com/e/er?s=2255121&lid=25390&elqTrackId=fe48595a525340d8a77ad34c160a1fa5&utm_campaign=PROMO_RHE_CCH_...
Effective URL: https://www.rheumatologyadvisor.com/clinicalchallenge/gout-pegloticase-allopurinol-hyperuricemia-tophi/?utm_source=promo&utm_medium=...
Submission: On April 24 via manual from US — Scanned from DE
Effective URL: https://www.rheumatologyadvisor.com/clinicalchallenge/gout-pegloticase-allopurinol-hyperuricemia-tophi/?utm_source=promo&utm_medium=...
Submission: On April 24 via manual from US — Scanned from DE
Form analysis
2 forms found in the DOMGET /
<form id="search-form" role="search" method="get" class="search-form" action="/">
<label>
<span class="screen-reader-text">Search for:</span>
<input type="search" class="search-field" placeholder="Search" value="" name="s">
</label>
<input type="submit" class="search-submit" value="GO">
</form>
<form class="HMIRegistration__form ismedical" novalidate="">
<div class="HMIRegistration__row ">
<div class="HMIRegistration__column u-col12">
<div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="email" id="root_email" label="email" placeholder="*E-mail Address" value="">
<div></div>
</div>
</div>
</div>
<div class="HMIRegistration__row ">
<div class="HMIRegistration__column u-col12">
<div class="HMIRegistration__form-control HMIRegistration__input "><input class="form-control" type="password" id="root_password" label="password" placeholder="*Password" value="">
<div></div>
</div>
</div>
</div>
<div class="HMIRegistration__row ">
<div class="HMIRegistration__column u-col12">
<div class="HMIRegistration__checkbox"><span class="HMIRegistration__sprite"><span class="HMIRegistration__sprite-border "></span><span class="HMIRegistration__sprite-checkmark "><svg width="15" height="15" class="widget-svg">
<path class="checkmark" d="M5.6,13.4C3.7,11.6,1.9,9.8,0,8c0.8-0.8,1.6-1.6,2.3-2.3c1.1,1,2.2,2.1,3.3,3.1c2.4-2.4,4.7-4.8,7-7.2 c0.8,0.8,1.5,1.6,2.3,2.3C11.9,7,8.8,10.2,5.6,13.4z"></path>
</svg></span><span class="HMIRegistration__sprite-fill "></span></span><span class="HMIRegistration__text ">Keep me signed in</span></div>
</div>
</div>
<p class="HMIRegistration__text linkToForgetPword ismedical"><a href="#" class="HMIRegistration__link ismedical">Forgot your password?</a></p><button class="HMIRegistration__submit ismedical" type="submit">Login</button>
<p class="HMIRegistration__text goToRegister ismedical"><a href="#" class="HMIRegistration__link ismedical">Do not have an account yet?<strong> Register</strong></a></p>
</form>
Text Content
Menu SECTIONS * News * Features * CME * Clinical Tools * Conferences * Special Collections * Multimedia * Diagnosis & Disease Info * Topics * Axial Spondyloarthritis * Connective Tissue Disease * Crystal Arthropathies * Diseases of Bone and Cartilage * General Medicine * General Rheumatology * Infection in Rheumatic Disease * Musculoskeletal Pain * Myositis * Osteoarthritis * Pediatric Rheumatology * Practice Management * Psoriatic Arthritis * Rheumatoid Arthritis * Sjögren Syndrome * Systemic Lupus Erythematosus * Vasculitis * Haymarket Medical Network * Cancer Therapy Advisor * Clinical Advisor * Clinical Pain Advisor * Dermatology Advisor * Endocrinology Advisor * Gastroenterology Advisor * Hematology Advisor * Infectious Disease Advisor * MPR * Medical Bag * Neurology Advisor * Oncology Nurse Advisor * Ophthalmology Advisor * Optometry Advisor * Psychiatry Advisor * Pulmonology Advisor * Rare Disease Advisor * Renal and Urology News * Rheumatology Advisor * The Cardiology Advisor Search for: Part of the * News and Features * CME * Conferences * Clinical Tools * Special Collections * Multimedia SEVERE GOUT REFRACTORY TO CONVENTIONAL THERAPY By Clinical Content Hub S: A 56-year-old man presents for management of podagra. O: Imaging of the right foot shows radiolucency of the metaphysis of the first metatarsal, suggestive of gout. A: The patient is started on allopurinol. Over the course of 3 visits in 6 months, his serum urate levels partially decrease, but his symptoms progress to the point where he experiences weekly flares. P: Treatment is reviewed with the patient, and he is switched to pegloticase with methotrexate. He is cautioned to refrain from alcohol and triggering foods. He is scheduled to return in 1 month for monitoring. Introduction Many factors may contribute to hyperuricemia, which is often associated with the presence of conditions such as hypertension, congestive heart failure, diabetes, kidney disease, and obesity, as well as a family history of gout. Treatments for these conditions (eg, thiazide diuretics, often prescribed for mild hypertension) are also associated with increases in serum urate levels, which can cause gout. These cases of gout may be particularly resistant to conventional therapies and require strategies designed to lower serum urate levels, such as uricase agents.1,2 Case Scenario Tom is a 56-year-old White man who works as a supervisor in a tool-making factory. He spends much of his day on his feet and frequently goes out after work for drinks with his peers. His wife works as a hospital nurse, often on a later shift, which leaves him alone in the evenings. He and his wife have no children at home. Tom is overweight, and he eats at diners and sports bars 3 to 4 times per week. He usually orders cheeseburgers or fried seafood with fries. He has 2 to 3 beers with dinner, followed by a few more drinks at home. Outside of work, he leads a sedentary lifestyle, generally sitting in front of the television until he falls asleep. Presentation Tom is referred to you by his primary care physician for a history of podagra, although he is in no acute distress at the time of your examination. Personal and Family History Tom reveals a history of hypertension, chronic kidney disease stage 2, coronary artery disease (status: post-stent placement), and metabolic syndrome. Tom describes recurring episodes, which occur several times per year, of pain and swelling in his great toe; the frequency of these episodes has recently increased from every few years to every few months. Both he and his wife have noticed that these episodes are associated with eating shellfish and commonly occur during football season, when he typically consumes more alcohol. His family history is notable for the presence of obesity in both parents and 2 siblings. He also has an uncle with gout. Prior Medications Tom has been treated for 20 years for hypertension. He is currently taking a thiazide diuretic, an angiotensin-converting enzyme (ACE) inhibitor, and a beta blocker. He also takes low-dose aspirin. Clinical Examination On examination, Tom appears to be in no acute distress. General examination is largely unremarkable except for the presence of generalized obesity and mild hypertension. Examination of his joints and extremities reveals bilateral hallux valgus with slight fluctuance of the first metatarsal phalangeal joint of the right foot, without warmth or redness. Imaging Studies Imaging obtained of Tom’s feet shows radiolucency of the metaphysis of the first metatarsal on the right foot, suggestive of gouty erosions and slight soft tissue haziness. Laboratory Findings Tom’s serum urate level is 9.5 mg/dL, his glomerular filtration rate is 45 mL/min, and his creatinine level is 1.6 mg/dL. His laboratory findings are otherwise normal. Diagnosis Tom is diagnosed with gouty arthritis and hyperuricemia. Treatment Tom is started on 100 mg allopurinol, with plans to increase his dosage by 100 mg each month in an effort to achieve a target serum urate level of 6 mg/dL or lower. Tom is concurrently started on colchicine 6 mg every other day. Follow-Up Visit: 4 Months Later Tom reports intermittent adherence to allopurinol 200 mg/day. He has experienced recurrent episodes of gout, which initially worsened when he began taking allopurinol. Clinical examination reveals fullness in the right knee, along with limited effusion and a bulge sign; it also shows warmth over the left midfoot. Laboratory assessment reveals a serum urate level of 8 mg/dL. You instruct Tom to increase his allopurinol dosage to 300 mg/day, maintain colchicine at 6 mg every other day, and return for a follow-up visit in 3 months. Acute Relapse: 1 Month Later You receive a call from Tom, who reports now-weekly occurring flares of gout. He has also noticed the development of 2 new nodules: near his elbow and on the dorsum of his right foot, near his great toe. He reports that he has continued to use allopurinol, typically 200 to 300 mg/day. Follow-Up Visit: 1 Week Later You see Tom in the clinic 1 week later, and laboratory assessment indicates that his serum urate level has increased to 8.5 mg/dL. He has several swollen joints, as well as nodules over his foot with characteristic skin translucency and an underlying whitish discoloration, suggestive of gouty tophi. You discuss various therapeutic options with him, including a change in his xanthine oxidase inhibitor treatment or the addition of a uricosuric agent. You mutually elect to initiate pegloticase in combination with methotrexate to prevent immunogenicity. You caution him about the need to abstain from alcohol, and you plan to initiate the pegloticase regimen when you have confirmed that his glucose-6-phosphate dehydrogenase (G6PD) level is normal. You recommend that he return for another follow-up visit in 1 month. Discussion of Uricase Treatment Many agents have been approved for the treatment of gout, which is achieved through a combination approach. Early flares of gout should be treated with any monotherapy or combination of colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral or intra-articular steroids to reduce inflammation and pain around the joints. An interleukin (IL)-1 blocker should be considered for patients with repeated flares, as well as patients in whom side effects or comorbid conditions contraindicate first-line therapies.3 Because gout is a chronic condition, the treatment of repeated flares includes the addition of urate-lowering therapies (ULTs) such as allopurinol, the preferred first-line therapy, to alleviate acute symptoms and prevent future attacks via reduced production of serum urate.3,4 Febuxostat is a second-line ULT because of concerns regarding its potential greater cardiovascular toxicity. Patients are also counseled to avoid foods that are high in purine (eg, seafood, red meat, and organ meats), which contribute to serum urate accumulation; they are also counseled to substantially reduce their consumption of beer and hard alcohol.4 Despite lifestyle modifications and the use of conventional ULTs, nearly 2% of patients with gout continue to experience flares and their serum urate levels remain elevated.5 Desired serum urate levels are <6 mg/dL (360 µmol/L) for all patients and <5 mg/dL (300 µmol/L) for patients with visible tophi.3 For patients with severe refractory gout (particularly patients with tophaceous disease), pegloticase is an alternative therapy.3,5 Pegloticase has shown efficacy in the rapid resolution of tophi and can significantly reduce serum urate levels; compared with other types of ULTs, pegloticase functions through a unique mechanism that involves the enzymatic degradation of serum urate.5 Common drug-related immunogenicity and anti-pegloticase antibody challenges can be managed by coadministration of medications such as methotrexate or mycophenolate mofetil, thereby extending the duration of pegloticase efficacy.6,7 -------------------------------------------------------------------------------- Take Our Survey -------------------------------------------------------------------------------- Acknowledgments Kenneth G. Saag, MD, MSc, is the division director of Clinical Immunology and Rheumatology and director of the Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center at the University of Alabama at Birmingham. Dr Saag is also the founding director of the UAB Center of Research Translation in Gout and Hyperuricemia. References 1. Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse (Basel). 2016;3(3-4):242-252. doi:10.1159/000443769 2. McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121-129. doi:10.1002/art.33315 3. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707. 4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180 5. Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-S38. doi:10.1016/j.semarthrit.2020.04.011 6. Botson JK, Saag K, Peterson J, et al. A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings. Arthritis Rheumatol. 2023;75(2):293-304. doi:10.1002/art.42335 7. Khanna PP, Khanna D, Cutter G, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2021;73(8):1523-1532. doi:10.1002/art.41731 Posted by Haymarket’s Clinical Content Hub. The editorial staff of Rheumatology Advisor had no role in this content’s preparation. Reviewed March 2023 * * Latest News Your top articles for Monday siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Loneliness, Social Isolation Affected Mental Health of Patients With Rheumatic Disease During COVID-19 Pandemic James Maitlall, MD 24 April 2023 rheumatologyadvisor.com Researchers studied the mental health outcomes of patients with rheumatic disease during the COVID-19 pandemic. siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Concurrent Skin and Joint Onset May Indicate More Severe PsA Jessica Nye, PhD 24 April 2023 rheumatologyadvisor.com Researchers sought to determine the risk factors predicting disease activity status in patients with psoriatic arthritis. siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Cardiovascular Advantage Diminishes Among Women With CKD With High BP Natasha Persaud 24 April 2023 rheumatologyadvisor.com The association between sex and cardiovascular risk is significantly modified by systolic blood pressure levels. siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Cybercriminals Pose a Growing Threat to Health Care Providers John Schieszer, MA 24 April 2023 rheumatologyadvisor.com Ransomware attacks are on the upswing due to the advent of novel technology platforms. siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Black Primary Care Providers Linked to Better Outcomes for Black Patients Haymarket Media 24 April 2023 rheumatologyadvisor.com Greater Black representation in the primary care provider workforce is associated with better population health measures… siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Placebo Plus Methadone Improves Opioid Use Disorder Treatment Retention Haymarket Media 24 April 2023 rheumatologyadvisor.com A conditioned open-label placebo (C-OLP) may be a beneficial, low-risk adjunct to methadone treatment of opioid use disorder. SIGN INFor More Personalized News * Haymarket Medical NetworkTop Picks Upadacitinib Shows Significant Efficacy in the Treatment of Moderate RA Patients With Early RA Who Receive T2T Management Report Fewer Excess CV Events Machine Learning Accurately Predicts Biologic Discontinuation in Psoriasis * * Loading... Powered By siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Addressing the Patient with Type 2 Diabetes Mellitus (T2DM) and Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Haymarket Media 14 April 2023 mycme.com siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Clinical Connections in COVID-19: Innovative Care for Hospitalized Patients Haymarket Media 21 April 2023 mycme.com siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Improving the Co-management of Moderate to Severe Pediatric and Adult Atopic Dermatitis in Primary Care and Specialty Settings Haymarket Media 31 March 2023 mycme.com siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 What Would You Do Next? Case-based Strategies in Moderate-to-Severe Asthma Haymarket Media 20 April 2023 mycme.com siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Cell-Depleting Therapies in Multiple Sclerosis: Balancing Efficacy and Safety Profiles Haymarket Media 31 March 2023 mycme.com siteName Rheumatology Advisor siteURL https://www.rheumatologyadvisor.com siteID 18 Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients Haymarket Media 28 March 2023 mycme.com Show More WANT TO READ MORE? Please login or register first to view this content. Login Register Do Not Sell or Share My Personal Information * ABOUT * ADVERTISE * CONNECT Remarkable healthcare content Cancer Therapy Advisor Clinical Advisor Clinical Pain Advisor Dermatology Advisor Endocrinology Advisor Gastroenterology Advisor Hematology Advisor Infectious Disease Advisor MPR McKnight’s Home Care McKnight’s Long-term Care McKnight’s Senior Living Medical Bag Neurology Advisor Oncology Nurse Advisor Ophthalmology Advisor Optometry Advisor Psychiatry Advisor Pulmonology Advisor Rare Disease Advisor Renal and Urology News Rheumatology Advisor The Cardiology Advisor myCME Copyright © 2023 Haymarket Media, Inc. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Close more info about Severe Gout Refractory to Conventional Therapy LOG IN TO RHEUMATOLOGY ADVISOR PLEASE LOG IN USING YOUR PASSWORD. *Required Keep me signed in Forgot your password? Login Do not have an account yet? Register Close more info about Severe Gout Refractory to Conventional Therapy JOIN THE CREATING YOUR FREE ACCOUNT WITH RHEUMATOLOGY ADVISOR ALLOWS YOU ACCESS TO EXCLUSIVE CONTENT, INCLUDING CASE STUDIES, DRUG INFORMATION, CME AND MORE ACROSS OUR GROWING NETWORK OF CLINICAL SITES. *Required *ProfessionCertified Diabetes EducatorClinical Nurse SpecialistConsumer / PatientDentistDietitian / NutritionistGenetic CounselorNurseNurse PractitionerOther Healthcare ProfessionalPharmacistPhysicianPhysician AssistantPsychologistResidentStudent *SpecialtyAllergy / ImmunologyAnesthesiologyBariatric MedicineCardiologyComplementary / Alternative MedicineCritical Care MedicineDentalDermatologyDiabetesEmergency MedicineEndocrinologyFamily Medicine / General PracticeGastroenterology / ProctologyGeriatric MedicineHematologyHematology / OncologyHospitalistInfectious DiseaseInfusion TherapyInternal MedicineLong-Term CareNephrologyNeurologyNutritionObstetrics / GynecologyOncologyOphthalmologyOptometryOrthopedicsOtolaryngologyPain MedicinePathologyPediatricsPharmacyPhysical Medicine / RehabilitationPsychiatryPublic Health / Preventive MedicinePulmonologyRadiology / Nuclear MedicineRheumatologySports MedicineSurgeryUrologyOther *CountryUnited States --State--AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington, D.C.West VirginiaWisconsinWyoming REGISTER FOR EMAIL NEWSLETTERS Rheumatology Advisor Update Register Already have an account with one of our brands? LOG IN Terms and Conditions | Privacy Policy DO NOT SELL OR SHARE MY PERSONAL DATA When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link. More information Accept MANAGE CONSENT PREFERENCES STRICTLY NECESSARY COOKIES Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. * FUNCTIONAL COOKIES Always Active These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. DO NOT SELL PERSONAL INFORMATION Do Not Sell Personal Information * SOCIAL MEDIA COOKIES Switch Label label These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools. * PERFORMANCE COOKIES Switch Label label These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. * TARGETING COOKIES Switch Label label These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. Back Button PERFORMANCE COOKIES Search Icon Filter Icon Clear checkbox label label Apply Cancel Consent Leg.Interest Switch Label label Switch Label label Switch Label label Confirm My Choices ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789-_~ x